The last few PR’s make it clear that Brilacidin
Post# of 72447
(Total Views: 532)
Posted On: 03/17/2020 10:55:32 AM
The last few PR’s make it clear that Brilacidin is being tested as both a vaccine and treatment for COVID-19. The focus on today’s PR is that Brilacidin is being tested “with a leading public health-focused U.S. university and top coronavirus expert.”
Separately, Brilacidin is scheduled to be tested this week in one of the Regional Biocontainment Lab (RBL). IMO the vaccine testing could be as a stand-alone treatment or as an adjuvant agent as a critical component. We will probably see a separate PR soon on the RBL testing.
If initial testing is successful per the 2/24/20 PR:
“Should laboratory tests support Brilacidin’s antiviral activity against SARS-CoV-2 (COVID-19), and potentially other RNA viruses, the Company will look to expedite research and clinical development of Brilacidin as a potential antiviral therapy via pharmaceutical partnerships, academic collaborations and government grants.”
Also noteworthy from the 2/24/20 PR “Discussions also are underway with a government-funded virology laboratory in Asia to assess Brilacidin across a range of RNA viruses.” I personally believe that President Trump will not sit back and allow Brilacidin to be licensed outside the U.S. with the realization that China currently controls a vast majority of the antibiotic market. A strong push to have a U.S. based solution combined with a heightened sense of urgency work in favor Brilacidin to be used to fight the COVID-19 pandemic.
The fact that Brilacidin has been tested to be safe and effective on human testing in 4 separate Phase 1 trials and 3 separate Phase 2 trials also separates it from most of the other tested alternative drugs. It also could be a factor in greatly accelerating getting Brilacidin to the public.
I have stated before that I do not believe it will be business as usual in the process of getting life-saving treatment out to those in need.
The following excerpts are from today’s announcement:
“Innovation Pharmaceuticals Brilacidin to be Researched as Possible Novel Coronavirus (COVID-19) Vaccine; Brilacidin Now Being Tested as Drug and Vaccine at Different Institutions”
“virologists plan to evaluate the potential antiviral properties of Brilacidin, the Company’s lead defensin-mimetic drug candidate, toward developing Brilacidin as a potential novel coronavirus (COVID-19) vaccine.”
“Vaccines containing defensins as adjuvants have been shown, both in vivo and in vitro, to activate the primary innate antiviral immune response and mediate other immunomodulatory activities against a number of viruses, including coronaviruses “Defensins and their mimetics, like Brilacidin, thus represent promising therapeutics developed as vaccines to target COVID-19.”
“This new research is independent of that being conducted on Brilacidin at one of the U.S. 12 Regional Biocontainment Labs (RBL). The RBL is testing Brilacidtin’s potential inhibitory activity as a small molecule drug against SARS-CoV-2, the novel coronavirus responsible for COVID-19.”
Separately, Brilacidin is scheduled to be tested this week in one of the Regional Biocontainment Lab (RBL). IMO the vaccine testing could be as a stand-alone treatment or as an adjuvant agent as a critical component. We will probably see a separate PR soon on the RBL testing.
If initial testing is successful per the 2/24/20 PR:
“Should laboratory tests support Brilacidin’s antiviral activity against SARS-CoV-2 (COVID-19), and potentially other RNA viruses, the Company will look to expedite research and clinical development of Brilacidin as a potential antiviral therapy via pharmaceutical partnerships, academic collaborations and government grants.”
Also noteworthy from the 2/24/20 PR “Discussions also are underway with a government-funded virology laboratory in Asia to assess Brilacidin across a range of RNA viruses.” I personally believe that President Trump will not sit back and allow Brilacidin to be licensed outside the U.S. with the realization that China currently controls a vast majority of the antibiotic market. A strong push to have a U.S. based solution combined with a heightened sense of urgency work in favor Brilacidin to be used to fight the COVID-19 pandemic.
The fact that Brilacidin has been tested to be safe and effective on human testing in 4 separate Phase 1 trials and 3 separate Phase 2 trials also separates it from most of the other tested alternative drugs. It also could be a factor in greatly accelerating getting Brilacidin to the public.
I have stated before that I do not believe it will be business as usual in the process of getting life-saving treatment out to those in need.
The following excerpts are from today’s announcement:
“Innovation Pharmaceuticals Brilacidin to be Researched as Possible Novel Coronavirus (COVID-19) Vaccine; Brilacidin Now Being Tested as Drug and Vaccine at Different Institutions”
“virologists plan to evaluate the potential antiviral properties of Brilacidin, the Company’s lead defensin-mimetic drug candidate, toward developing Brilacidin as a potential novel coronavirus (COVID-19) vaccine.”
“Vaccines containing defensins as adjuvants have been shown, both in vivo and in vitro, to activate the primary innate antiviral immune response and mediate other immunomodulatory activities against a number of viruses, including coronaviruses “Defensins and their mimetics, like Brilacidin, thus represent promising therapeutics developed as vaccines to target COVID-19.”
“This new research is independent of that being conducted on Brilacidin at one of the U.S. 12 Regional Biocontainment Labs (RBL). The RBL is testing Brilacidtin’s potential inhibitory activity as a small molecule drug against SARS-CoV-2, the novel coronavirus responsible for COVID-19.”
(17)
(1)